Dissertation Defended: Jasmin Kaivola
Jasmin Kaivola from the Ivaska lab successfully defended her PhD thesis “Biomechanical Tumour Matrix” on Friday the 29th of November 2024. Her opponent was Professor Rachel Lennon from the Cell-Matrix Research Center, University of Manchester, UK.
Summary of the Dissertation:
The interplay between mechanical forces and the tumour microenvironment is critical in cancer progression, influencing tumour growth, metastasis and therapy resistance. Integrins, which mediate cell adhesion to the extracellular matrix (ECM), transmit mechanical signals that regulate key cellular processes including proliferation and migration. These mechanical forces modulate integrin activity, altering the cytoskeleton and signalling networks, thereby promoting cancer invasiveness and metastasis. The tumour matrix’s physical properties, such as stiffness, further drive cancer progression. Cancer-associated fibroblasts remodel the ECM, increasing matrix stiffness and enhancing mechanotransduction pathways. Moreover, cancer-associated adipocytes contribute to metabolic reprogramming and inflammation, creating a feedback loop that accelerates tumour growth. Understanding these molecular mechanisms is crucial for developing therapies that disrupt these pathways to inhibit cancer progression and metastasis.
In this thesis, I have explored how reintroducing mechanical forces lost in cancer, owing to increased tissue rigidity, can downregulate oncogenic signalling activity. Specifically, stretching and vibrating vocal fold cancer cells lead to nucleocytoplasmic localisation of the oncogenic transcription factors YAP/TAZ and β-catenin. Additionally, I have investigated the role of healthy adipocytes in the breast tumour microenvironment, demonstrating that secretion of the adipocrine factor IGFBP2 can act as a protective barrier against breast cancer progression. Lastly, I examined the role of the integrin inactivator SHANK3 in KRAS-driven cancers, showing that disrupting the SHANK3-KRAS interaction can induce cell death in KRAS-mutant cancer cells through hyperactivation of the MAPK-ERK pathway. Collectively, these findings offer novel strategies to inhibit and target cancer progression across different cancer types.
Download Doctoral Dissertation at UTUPub: https://urn.fi/URN:ISBN:978-951-29-9938-5
Recent Posts
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026
- Rector Widen Visited Our Centre Åbo Akademi University Rector, Gunilla Widén, visited our Centre on Wednesday, February 25th, to learn Read moreFebruary 27, 2026
- Laura Elo is awarded the Leif C. Groop Award for outstanding research on type 1 diabetesLaura Elo a group leader at Turku Bioscience is awarded the Leif C. Groop Award Read moreFebruary 23, 2026